Different mutations in the same codon of the proteolipid protein gene,PLP, may help in correlating genotype with phenotype in Pelizaeus-Merzbacher disease/X-linked spastic paraplegia (PMD/SPG2)
- 15 January 1999
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics
- Vol. 82 (2) , 132-139
- https://doi.org/10.1002/(sici)1096-8628(19990115)82:2<132::aid-ajmg6>3.0.co;2-4
Abstract
Pelizaeus-Merzbacher disease/X-linked spastic paraplegia (PMD/SPG2) comprises a spectrum of diseases that range from severe to quite mild. The reasons for the variation in severity are not obvious, but suggested explanations include the extent of disruption of the transmembrane portion of the proteolipid protein caused by certain amino acid substitutions and interference with the trafficking of the PLP molecule in oligodendrocytes. Four codons in which substitution of more than one amino acid has occurred are available for examination of clinical and potential structural manifestations: Valine 165 to either glutamate or glycine, leucine 045 to either proline or arginine, aspartate 202 to asparagine or histidine, and leucine 223 to isoleucine or proline. Three of these mutations, Val165Gly, Leu045Pro, and Leu223Ile have not been described previously in humans. The altered amino acids appear in the A-B loop, C helix, and C-D loop, respectively. We describe clinically patients with the mutations T494G (Val165Gly), T134C (Leu045Pro), and C667A (Leu223Ile). We discuss also the previously reported mutations Asp202Asn and Asp202His. We have calculated the changes in hydrophobicity of short sequences surrounding some of these amino acids and compared the probable results of the changes in transmembrane structure of the proteolipid protein for the various mutations with the clinical data available on the patients. While the Val165Glu mutation, which is expected to produce disruption of a transmembrane loop of the protein, produces more severe disease than does Val165Gly, no particular correlation with hydrophobicity is found for the other mutations. As these are not in transmembrane domains, other factors such as intracellular transport or interaction between protein chains during myelin formation are probably at work. Am. J. Med. Genet. 82:132–139, 1999.Keywords
This publication has 22 references indexed in Scilit:
- Conservation of Topology, But Not Conformation, of the Proteolipid Proteins of the Myelin SheathJournal of Neuroscience, 1997
- Monoclonal Antibody O10 Defines a Conformationally Sensitive Cell-Surface Epitope of Proteolipid Protein (PLP): Evidence that PLP Misfolding Underlies Dysmyelination in Mutant MiceJournal of Neuroscience, 1996
- A cellular mechanism governing the severity of Pelizaeus–Merzbacher diseaseNature Genetics, 1996
- Orientation of myelin proteolipid protein in the oligodendrocyte cell membraneNeurochemical Research, 1996
- Adhesive properties of proteolipid protein are responsible for the compaction of CNS myelin sheathsJournal of Neuroscience, 1995
- Proteolipid protein gene dosage effect in Pelizaeus–Merzbacher diseaseNature Genetics, 1994
- Many naturally occurring mutations of myelin proteolipid protein impair its intracellular transportJournal of Neuroscience Research, 1994
- Genetics of Pelizaeus-Merzbacher DiseaseDevelopmental Neuroscience, 1993
- IDENTIFYING NONPOLAR TRANSBILAYER HELICES IN AMINO ACID SEQUENCES OF MEMBRANE PROTEINSAnnual Review of Biophysics, 1986
- A simple method for displaying the hydropathic character of a proteinJournal of Molecular Biology, 1982